Kidney transplant recipients undergo lifelong monitoring of allograft function and evaluation
for transplant complications. The current monitoring paradigm utilizes blood, urine, and …

The donor-derived cell-free DNA (ddcfDNA) is found in the plasma and urine of kidney
transplant recipients and displays notable potential in diagnosing rejection, specifically …

Extracellular vesicle‐bound DNA (evDNA) is an understudied extracellular vesicle (EV)
cargo, particularly in cancer‐unrelated research. Although evDNA has been detected in …

Circulating donor‐specific antibodies (DSA) do not necessarily indicate antibody‐mediated
rejection (ABMR). Here, we evaluated the diagnostic value of donor‐derived cell‐free DNA …

Background BK polyomavirus‐associated nephropathy (BKPyVAN) carries a risk of
irreversible allograft injury. While detection of BK viremia and biopsy assessment are the …

The early detection of acute rejection in the allograft is important as it provides an
opportunity for timely therapeutic intervention in order to preserve graft function and achieve …

Infection and rejection are major complications that impact transplant longevity and recipient
survival. Balancing their risks is a significant challenge for clinicians. Current strategies …

Monitoring kidney transplants for rejection conventionally includes serum creatinine,
immunosuppressive drug levels, proteinuria, and donor-specific antibody (DSA). Serum …

Early detection of kidney transplant (KT) rejection remains a challenge in patient care. Non-
invasive biomarkers hold high potential to detect rejection, adjust immunosuppression, and …

Donor-derived cell-free DNA (dd-cfDNA) based liquid kidney biopsies have the potential to
detect the chances of kidney transplant rejection. Several studies have found that dd-cfDNA …